Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

A broad syndicate has funded NewAmsterdam with a $196 million (€160 million) series A round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm for dyslipidemia.

Forbion, Morningside Ventures and Ascendant BioCapital led the round, which will fund a Phase III program for obicetrapib. NewAmsterdam Pharma B.V. acquired the program from Amgen Inc. (NASDAQ:AMGN) last year...